Comparison
BPC-157 vs Omega-3 (EPA/DHA)
Side-by-side of BPC-157 and Omega-3 (EPA/DHA). Every row below is pulled from the compound schema and will update as our data grows. For deeper reads, follow through to each compound page.
BPC-157
BPC-157 peptide profile: pentadecapeptide body protection compound 157. Preclinical data on tendon, gut healing, recovery. No human RCTs as of 2026.
Omega-3 (EPA/DHA)
Omega 3 fish oil profile: EPA/DHA marine fatty acids, 2-4 g/day cuts triglycerides 20-30%, REDUCE-IT showed 25% cardiovascular risk reduction on icosapent eth.
Effects at a glance
BPC-157
- •Preclinical models show accelerated tendon-to-bone and ligament healing after surgical or chemical injury
- •Rodent studies report mucosal protection and faster recovery from NSAID-induced and colitis-induced gut damage
- •Anecdotal human protocols use 250 to 500 mcg twice daily subcutaneously near the injury site
- •No completed phase II or III human RCTs as of 2026, so efficacy and long-term safety remain unestablished
- •Banned by WADA since 2022 under the S0 non-approved substances category for competitive athletes
- •Theoretical angiogenic concern means avoidance is prudent in active malignancy until human data exists
Omega-3 (EPA/DHA)
- •Reduces fasting triglycerides 20-50% at 2-4 g/day in hypertriglyceridemic patients
- •REDUCE-IT showed 25% relative risk reduction in major CV events at 4 g/day icosapent ethyl
- •Modest antidepressant effect (SMD ~0.40) for EPA-dominant formulations at 1-2 g/day
- •Atrial fibrillation incidence rises ~30-50% at 4 g/day; relevant for older patients with pre-existing CV disease
- •Tissue omega-3 index (RBC EPA + DHA) target ~8%; Western baseline typically 4-5%
- •Triglyceride and re-esterified triglyceride forms absorb ~70% better than ethyl esters in fasted state
Side-by-side
| Attribute | BPC-157 | Omega-3 (EPA/DHA) |
|---|---|---|
| Category | peptide | supplement |
| Also known as | Body Protection Compound-157, Pentadecapeptide BPC-157 | fish oil, EPA, DHA, marine omega-3 |
| Half-life (hr) ↗ | 4 | 48 |
| Typical dose (mg) ↗ | 0.25 | 2000 |
| Dosing frequency | daily (anecdotal protocols) | 1 to 2 times daily with food |
| Routes | subcutaneous, intramuscular, oral | oral |
| Onset (hr) | - | 4 |
| Peak (hr) | - | 12 |
| Molecular weight | - | 302.45 |
| Molecular formula | C62H98N16O22 | C20H30O2 (EPA); C22H32O2 (DHA) |
| Mechanism | Proposed upregulation of VEGFR2 and nitric oxide pathways, modulation of growth-hormone receptor expression, and stabilization of gut-brain axis signaling. Mechanism remains largely preclinical. | Substitutes arachidonic acid in membrane phospholipids, shifting eicosanoid production toward less-inflammatory 3-series prostaglandins and 5-series leukotrienes. Activates PPAR-alpha to lower hepatic VLDL/triglyceride synthesis. DHA modulates synaptic membrane fluidity and neuronal function. |
| Legal status | Not FDA approved; research-use-only grey market; banned by WADA (2022) | Dietary supplement; prescription forms (icosapent ethyl, omega-3 acid ethyl esters) for severe hypertriglyceridemia |
| WADA status | banned | allowed |
| DEA / Rx | Not FDA approved; not scheduled; research-chemical status | Not scheduled |
| Pregnancy | Insufficient data | Recommended at 200 to 600 mg DHA/day for fetal development |
| CAS | 137525-51-0 | 10417-94-4 |
| PubChem CID | 9941957 | 446284 |
| Wikidata | Q4835418 | Q207688 |
Safety profile
BPC-157
Common side effects
- injection-site irritation
- nausea
- headache (anecdotal)
Contraindications
- pregnancy
- active malignancy (theoretical angiogenic concern)
- no established safety profile in humans
Omega-3 (EPA/DHA)
Common side effects
- fishy aftertaste
- eructation (fish burps)
- mild dyspepsia
- loose stools at high doses
Contraindications
- fish allergy (use algal omega-3 alternative)
- active bleeding disorders
- scheduled surgery (discontinue 5-7 days prior)
Interactions
- warfarin and DOACs: additive antiplatelet effect at 2+ g/day; meaningful bleeding risk(moderate)
- aspirin and antiplatelet agents: additive bleeding risk at high doses(moderate)
- statins: complementary cardiovascular effects; no pharmacokinetic interaction(minor)
- antiarrhythmics: high-dose omega-3 increases AF risk; relevant in pre-existing arrhythmia(moderate)
Which Should You Take?
Omega-3 (EPA/DHA) comes out ahead for most readers on the criteria we weight: 3 catalogued goals, OTC dietary supplement, oral dosing, with a Tier-A outcome catalogued. BPC-157 is the right call when one of the conditionals below applies.
- → If your priority is post-training recovery, pick BPC-157.
- → If your priority is gut barrier and microbiome health, pick BPC-157.
- → If your priority is cardiovascular health, pick Omega-3 (EPA/DHA).
- → If your priority is healthspan extension, pick Omega-3 (EPA/DHA).
Edge case: If you want to avoid research-only / gray-market sourcing, Omega-3 (EPA/DHA) is the more accessible choice.
Default choice: Omega-3 (EPA/DHA). Lower friction to source, a Tier-A evidence outcome catalogued, and broader goal coverage. Reach for BPC-157 only if your priority sits squarely in the goals it owns above.
This verdict is generated from each compound's schema (goals, legal status, evidence outcomes, dosing route). It updates automatically as our compound data evolves; the deeper read sits on each individual compound page.
Common questions
What is the difference between BPC-157 and Omega-3 (EPA/DHA)?
BPC-157 and Omega-3 (EPA/DHA) differ in category (peptide vs supplement), mechanism, and typical dosing. See the side-by-side table for full details.
Which has a longer half-life, BPC-157 or Omega-3 (EPA/DHA)?
BPC-157 half-life is 4 hours; Omega-3 (EPA/DHA) half-life is 48 hours.
Can you stack BPC-157 with Omega-3 (EPA/DHA)?
Stack compatibility depends on mechanism overlap, legal status, and individual response. Check each compound page for specific interactions and contraindications before combining.
Go deeper